Seeking Novel Anti-tumour Antibodies

Xencor is a clinical-stage biopharmaceutical company focused on the discovery and development of bispecific antibodies and cytokine drugs. Xencor is currently seeking monoclonal antibodies directed against tumour-associated antigens, for incorporation into their clinically validated T cell engager platform.

Approaches of Interest

- The highest priority is given to novel, solid tumour targets
- There is also interest in antibodies against well-known tumour targets but with novel/differentiated epitopes
- Targets expressed specifically on tumour cells are of the highest interest, with stromal targets are still of interest
- Cancers of interest include but are not limited to ovarian, breast (especially TNBC), head and neck, lung, colon, prostate, kidney, oesophageal, bladder and liver
- Key data sets should include: Tumour vs normal expression (RNA and/or immunohistochemistry), antibody affinity and selectivity, and antibody binding to representative tumour cell lines

Out of scope

- Pancreatic and haematological cancers
- Checkpoint inhibition and activation of the complement system
- Antibody delivery methods and platform technologies for antibody production

Developmental Stages of Interest

- Xencor is open to approaches from the discovery stage through to clinical Phase II, with a particular interest in opportunities at the discovery/preclinical stage
- Opportunities with in vivo, in vitro and/or ex vivo validation will be accepted

Submission Information

Submission of one page, 200-300 word briefs are encouraged. Along with any optional supplementary information e.g. relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Xencor is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, research collaborations and sponsored research opportunities.